Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Targeting WNK1 suppresses acute myeloid leukemia progression and enhances sensitivity to venetoclax

ABSTRACT: The With-No-Lysine (WNK) kinase family plays critical roles in cellular signaling, yet its significance in acute myeloid leukemia (AML) remains unclear. Here, we demonstrate that WNK1 is a novel therapeutic target in AML. Analysis of public databases and primary patient samples reveals that WNK1, but not other WNK family members, is highly expressed in AML, particularly in adverse subtypes such as FLT3-ITD mutated AML. CRISPR dependency scores confirm WNK1 is essential for AML cell survival. Pharmacological inhibition of WNK1 using WNK463 or WNK11 significantly suppresses the proliferation of AML cell lines and primary blasts, induces apoptosis through upregulation of pro-apoptotic proteins Bim and Puma, and impedes tumor growth in mouse xenograft models without significant toxicity. Transcriptomic analysis indicates that WNK1 inhibition downregulates genes involved in DNA replication pathways, including MCM5, CHAF1B, and GINS2, whose high expression correlates with poor prognosis. Importantly, elevated WNK1 expression is associated with resistance to the BCL-2 inhibitor venetoclax, a frontline AML therapy. Combining WNK463 with venetoclax exhibits synergistic anti-leukemic effects in vitro, accompanied by enhanced Bim upregulation. In summary, our study identifies WNK1 as a key oncogenic driver in AML and establishes WNK1 inhibition as a promising therapeutic strategy that suppresses AML progression and sensitizes leukemia cells to venetoclax, providing a rationale for novel combination regimens to overcome drug resistance.

ORGANISM(S): Homo sapiens

PROVIDER: GSE333251 | GEO | 2026/05/29

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Identification of WNK1 as a therapeutic target to suppress IgH/MYC expression in multiple myeloma

Project description:Multiple myeloma (MM) remains a challenging hematological malignancy demanding innovative therapeutic strategies. Targeting MYC, the notorious yet traditionally undruggable oncogene, presents an appealing avenue. Here, using a genome-scale CRISPR/Cas9 screen, we identify the WNK lysine deficient protein kinase 1 (WNK1) as a regulator of MYC expression in MM cells. Genetic and pharmacological inhibition of WNK1 reduces MYC expression, and further, disrupts the MYC-dependent transcriptional program. Mechanistically, WNK1 inhibition attenuates the activity of the immunoglobulin heavy chain (IgH) enhancer, thus reducing MYC transcription when this locus is translocated near the MYC locus. WNK1 inhibition profoundly impacts MM cell behaviors, leading to growth inhibition, cell cycle arrest, senescence, and apoptosis. Importantly, the WNK inhibitor WNK463 synergizes with various anti-MM compounds, and inhibits MM growth in primary patient samples as well as xenograft mouse models. Collectively, our study uncovers WNK1 as a potential therapeutic target in MM.

2024-04-18 | PXD051532 |

WNK1 signalling regulates amino acid transport and mTORC1 activity to sustain AML growth

Project description:The lack of curative therapies for acute myeloid leukaemia (AML) remains an ongoing challenge despite recent advances in the understanding of the molecular basis of the disease. Here we identify the WNK1-OXSR1/STK39 pathway as a previously uncharacterised dependency in AML. We show that genetic depletion and pharmacological inhibition of WNK1 or its downstream phosphorylation targets OXSR1 and STK39 strongly reduce cell proliferation and induce apoptosis in leukemic cells in vitro and in vivo. Furthermore, we show that the WNK1-OXSR1/STK39 pathway controls mTOR signalling via regulating amino acid uptake through a mechanism involving the phosphorylation of amino acid transporters, such as SLC38A2. Our results demonstrate a critical role of the WNK1-OXSR1/STK39 pathway in regulating amino acid uptake and in AML maintenance. Moreover, our mode of action studies suggests that WNK1 and OXSR1/STK39 inhibitors could be effective in a broad range of cancer types.

2025-06-02 | PXD041902 | Pride

WNK1 enforces macrophage lineage fidelity

Project description:The appropriate development of myeloid progenitors into macrophages, the body’s professional phagocyte, is essential for organismal development, especially in mammals1. This dependence is exemplified by the observation that loss-of-function mutation in colony stimulating factor 1 receptor (CSF1R) results in multiple tissue abnormalities including osteopetrosis2. Despite this importance, little is known about the molecular and cell biological regulation of macrophage development. Here, we report the surprising finding that the chloride-sensing kinase With-no-lysine 1 (WNK1) is required for embryonic development of tissue-resident macrophages (TRMs). Myeloid-specific deletion of Wnk1 caused a dramatic loss of TRMs and subsequently disrupted organ development, induced systemic neutrophilia, and resulted in mortality between 3 and 4 weeks of age. Specifically, we observed that WNK1 absence stalled macrophage differentiation at the myeloid multipotent progenitor (MPP) stage, instead skewing MPP differentiation towards granulopoiesis. Mechanistically, the cognate CSF1R cytokine, macrophage-colony stimulating factor (M-CSF), triggers macropinocytosis in myeloid progenitors, which in turn induces phosphorylation of WNK1. Importantly, macropinocytosis by myeloid progenitors increases cytosolic chloride, which is directly sensed by WNK1. Perturbing chloride flux during macropinocytosis, inhibiting WNK1 chloride-sensing, and blocking macropinocytosis each skew progenitor differentiation from macrophage lineage to granulocyte lineage. Thus, we have uncovered a novel mechanism that links a cell biological process to a molecular circuit whereby WNK1 chloride-sensing and chloride flux act downstream of M-CSF-induced macropinocytosis by multipotent progenitors to ensure macrophage lineage fidelity.

2024-02-06 | GSE196336 | GEO

Meiotic completion of the spermatocytes requires the kinase WNK1

Project description:The kinase protein WNK1 is highly expressed and phosphorylated in the testis, suggesting possible functions in regulating male fertility. Indeed, conditional pachytene-spermatocyte Wnk1 knock-out mice generated using the novel Wnt7a-Cre failed to produce functional sperm which resulted from the primary spermatogenic arrest during mid-pachynema. Global transcriptomic approaches identified ‘translation’ as one of the impacted events in Wnk1-depleted spermatocytes.

2023-08-27 | GSE234068 | GEO

Repression of TRIM13 by chromatin assembly factor CHAF1B is critical for AML development

Project description:Acute myeloid leukemia (AML) is an aggressive blood cancer that stems from the rapid expansion of immature leukemic blasts in the bone marrow. Mutations in epigenetic factors represent the largest category of genetic drivers of AML. The chromatin assembly factor CHAF1B is a master epigenetic regulator of transcription associated with self-renewal and the undifferentiated state of AML blasts. Upregulation of CHAF1B, as observed in almost all AML samples, promotes leukemic progression by repressing transcription of differentiation factors and tumor suppressors. However, the specific factors regulated by CHAF1B and their contributions to leukemogenesis are unstudied. We analyzed RNAseq from mouse MLL-AF9 leukemic cells and bone marrow aspirates representing a diverse collection of pediatric AML samples and identified the E3 ubiquitin ligase TRIM13 as a target of CHAF1B-mediated transcriptional repression associated with leukemogenesis. We found that CHAF1B binds the promoter of TRIM13, resulting in its transcriptional repression. In turn, TRIM13 suppresses self-renewal of leukemic cells by promoting pernicious entry into the cell cycle through its nuclear localization and catalytic ubiquitination of cell cycle-promoting protein CCNA1. Overexpression of TRIM13 initially prompts a proliferative burst in AML cells that is followed by exhaustion, while loss of total TRIM13 or deletion of its catalytic domain enhanced leukemogenesis in AML cell lines and patient-derived xenografts. These data suggest that CHAF1B promotes leukemic development in part by repressing TRIM13 expression, and that this relationship is necessary for leukemic progression.

2023-06-01 | GSE231512 | GEO

Analysis of anti-CD3e-induced transcriptional changes in WNK1-deficient thymocytes

Project description:RNAseq was used to analyse transcriptional changes occuring in WNK1-expressing or WNK1-deficient DN3 thymocytes following injection of anti-CD3e

2020-10-26 | GSE136210 | GEO

RNA sequencing of WNK1 and SLUG co-overexpressed LNCaP cells

Project description:Human prostate cancer LNCaP cells Overexpressed with rat WNK 1 and human SLUG cDNA

2020-05-07 | GSE114154 | GEO

CD4+ T cell activation in absence of WNK1

Project description:Signaling from the T cell antigen receptor (TCR) on CD4+ T cells triggers the adaptive immune response by inducing T cell activation, proliferation, and differentiation. However, TCR signaling pathways are incompletely understood. Unexpectedly, we demonstrate that WNK1, a kinase previously implicated in osmoregulation in the kidney, is required for T-dependent antibody responses. We show that WNK1-OXSR1-STK39-dependent water influx through AQP3 is required for TCR signaling in CD4+ T cells and for entry into cell cycle. Additionally, by preventing ATR activation this signaling pathway is required for T cells to progress through the G2 phase of the cell cycle. Thus, TCR signaling via WNK1, OXSR1, STK39 and AQP3 leads to water entry that is essential for CD4+ T cell proliferation and hence T cell-dependent antibody responses.

2024-12-03 | GSE201228 | GEO

Transcriptomics changes upon WNK1 knockdown in JJN3 cells

Project description:We performed RNA-seq in JJN3 human multiple myeloma cells with or without WNK1 knockdown to profile global transcriptomic changes

2024-04-16 | GSE244668 | GEO